- Author: Kathy Keatley Garvey
The research appears in the February edition of the Zoological Journal of the Linnean Society.
The fossil, from the Cretaceous geological period and now part of the American Museum of Natural History collection, “was an extremely cool find,” said Boudinot, who is researching evolutionary and comparative anatomy in Jena under a two-year Alexander von Humboldt Research Fellowship. He received his UC Davis doctorate in entomology in 2020.
Boudinot, the lead researcher and corresponding author of the paper, describes the fossil as a “relatively large piece of Kachin amber containing three wingless adult female ants plus a wingless pupa.”
“The key points are that there is a remarkable diversity of evolutionarily intermediate or ‘missing link' ants in the Cretaceous fossil record, and folks have basically assumed that they were eusocial because wingless females—presumptive workers—had been found,” Boudinot said. “The fossil we discovered cuts through the uncertainty because of the pupa; this is the first ever pupa found from Mesozoic fossils, and we confirmed through the use of cutting-edge technology (µ-CT) that it is from the same species as one of the adults. Because pupae are immobile, it is reasonable that she was dropped during transportation by the adult wingless female.”
“Importantly, the transport of larvae and pupae--termed “brood transport”--is a unique feature of ants among all Hymenoptera, and is a critical social behavior,“ Boudinot said. “This fossil is the first evidence of nursing by wingless females, very strongly indicating that advanced social organization had evolved before the origin of the modern ants in the Early Cretaceous.”
“Taken altogether, this fossil opens a totally new pathway for the study of arthropod evolution: Paleoanatomy and paleosociobiology. There is far more to learn from fossils than previously realized!”
The focal amber piece originated from a deposit in theHukawng Valley,Kachin State, northern Myanmar, dated near the Albian–Cenomanian boundary.
Co-authors are Adrian Richter and Rolf Georg Beutel, Friedrich Schiller University Jena; Julian Katzke, Roberto Keller and Evan Economo, Okinawa Institute of Science and Technology Graduate University, Japan; Júlio C M Chaul, Federal University of Viçosa, Brazil; and Shûhei Yamamoto of Hokkaido University Museum, Hokkaido University.
Yamamoto discovered the fossil, Richter and Katzke generated and rendered the µ-CT data, and Beutel, Chaul and Economo were integral for shaping the conclusions, Boudinot said. “The study also represents a breakthrough in the application of µ-CT technology for taxonomy, as we were able to make very precise comparisons among the fossilized individuals, allowing me to revise the classification of the genus †Gerontoformica.”
Globally, there are more than 14,000 described species of ants, Boudinot says "As a community, we usually throw around the figure 20,000 as our rough total estimate for three reasons: (1) there is an incredible diversity of ants in tropical ecosystems that have yet to be formally named, (2) modern sequencing technology is allowing us to gain deep insights into the population structure and relationships of living species, thus revealing considerable hidden species-level diversity, and (3) there are over a thousand subspecies names in the ant literature which need to be re-evaluated as these could actually represent proper species. There is a ton of work to do, and Phil Ward and folk are making tremendous progress!"
Regarding extinct species, Boudinot says here are "almost as many fossil ants described as non-avian dinosaurs! As of today, the number stands at about 746 fossil species; of these, only about 50 are described from Mesozoic fossil deposits. This small fraction is critical, however, as they are the key to understanding the patterns of early evolution in the ants!"
- Author: Kathy Keatley Garvey
A blood plasma biomarker discovered in hospitalized COVID-19 patients may not only predict the severity of adult respiratory distress syndrome (ARDS) but further research may lead to inhibiting the progression, a team of eight University of California researchers announced today.
The UC researchers, primarily from the laboratory of UC Davis distinguished professor Bruce Hammock, found that four compounds in the blood of COVID-19 patients are highly associated with the disease. Their paper, “Plasma Linoleate Diols Are Potential Biomarkers for Severe COVID-19 Infections,” is published as open access in the current edition of Frontiers in Physiology.
ARDS, characterized by fluid build-up in the lungs, is the second leading cause of death in COVID-19 patients, next to viral pneumonia, according to the National Center for Biotechnology Information.
“Different outcomes from COVID-19 infections are both terrifying from a human health perspective and fascinating from a research perspective,” said UC Davis lead author and doctoral candidate Cindy McReynolds of the Hammock lab. “Our data provide an important clue to help determine what impacts the severity of COVID-19 outcomes. Initially, we focused on the immune response and cytokine profile as important drivers in severity, but considering what we now know from our study and others in the field, lipid mediators may be the missing link to answering questions such as why some people are asymptomatic while others die, or why some disease resolves quickly while others suffer from long-haul COVID.”
The compounds, known as leukotoxins and leukotoxin diols, originate from linoleic acid, the body's most abundant dietary fat, said Hammock, who holds a joint appointment in the Department of Entomology and Nematology and the UC Davis Comprehensive Cancer Center and directs the National Institute of Environmental Health Sciences (NEIHS) Superfund Research Program at UC Davis. “The leukotoxins (also called EpOMEs) are converted to the leukotoxin diols (also called DiHOMES) by the soluble epoxide hydrolase we work on.”
“So the leukotoxins and leukotoxin diols,” Hammock said, “are indicators of respiratory problems in COVID-19 patients as plasma biomarkers. They also present a pathway for reducing ARDS in COVID-19 if we could inhibit the soluble epoxide hydrolase, a key regulatory enzyme involved in the metabolism of immune resolving fatty acids.”
Professor John Imig, director and eminent scholar of the Medical College of Wisconsin's Drug Discovery Center, who was not involved in the study, said: “The COVID-19 pandemic has demonstrated that coronaviruses can have deadly consequences. Lung distress is a major reason for death in COVID-19 patients infected with the coronavirus (SARS-CoV-2). The findings of McReynolds et al. identified lipids called leukotoxin diols in the blood of COVID-19 patients that could act as a biomarker for lung distress. In addition, leukotoxin diols could be responsible for lung distress in COVID-19 patients. Excitingly, this suggest that therapies to lower leukotoxin diols could treat lung distress and prevent death in COVID-19 patients.”
“The findings presented in this paper bring important attention to a role for oxylipin metabolites in COVID-19 infections,” said Professor A. Daniel Jones of Michigan State University's Department of Biochemistry and Molecular Biology and director of the university's Research Technology Facility's Mass Spectrometry and Metabolomics Core. “Most notably, metabolites known as DiHOMEs which have been previously implicated in lung inflammation show promise for their potential to predict outcomes in COVID patients and guide therapeutic, and perhaps dietary interventions beneficial to human populations.” Jones, who was not involved in the study, serves as secretary of the Metabolomics Association of North America.
The UC Davis scientists used clinical data collected from six patients with laboratory-confirmed SARS-CoV-2 infection and admitted to the UC Davis Medical Center, Sacramento, and 44 healthy samples carefully chosen from the healthy control arm of a recently completed clinical study.
The Hammock lab's 50-year research on soluble epoxide hydrolase (sEH) and its inhibitors led the professor to found and direct EicOsis Human Health, a Davis-based company that is developing a potent soluble epoxide hydrolase inhibitor for pain relief. Epoxy fatty acids control blood pressure, fibrosis, immunity, tissue growth, depression, pain, inflammation and other processes.
But more recently, the Hammock lab has turned its attention to using sEH as a means to resolve inflammation associated with COVID-19 and the fibrosis that can follow.
Lipid metabolism researcher Ameer Taha of the UC Davis Department of Food Science and Technology pointed out that linoleic acid is an essential fatty acid present in only small amounts in our evolutionary diets. “In addition to nutritional and structural roles of linoleate, minor linoleate metabolites including the leukotoxin diols (also known as DiHOMEs) regulate a number functions including body temperature, cardiac health and vascular permeability. This study cautions that now with dietary linoleate levels at an all-time high, in periods of high stress as with COVID-19, these regulatory functions may become detrimental.”
The paper is the work of Hammock, McReynolds and Jun Yang of the Department of Entomology and Nematology and EicOsis Human Health; Irene Cortes-Puch of the Department of Entomology and Nematology, EicOsis Human Health, and the Department of Internal Medicine's Division of Pulmonary Critical Care and Sleep Medicine; Resmi Ravindran and Imran Khan of the Department of Pathology and Laboratory Medicine; Bruce G. Hammock of UC Davis Department of Veterinary Medicine, Aquatic Health; and Pei-an Betty Shih of the UC San Diego Department of Psychiatry.
“This study resulted from an exciting collaboration with Imran Khan and Angela Haczku of the UC Davis School of Medicine to identify potential biomarkers for differentiating the severity of COVID-19 diseases,” said Yang, the corresponding author.
The research drew financial support from several National Institutes of Health agencies: National Institute of Environmental Health Sciences (NIEHS) Superfund Research Program and R35 grant, National Institute of General Medical Sciences (NIGMS),and the National Institute of Mental Health (NIMH).
Resources:
- EicOsis: Developing a New Approach to Treat Pain
- Bruce Hammock: Lifetime Achievement Award from the Chancellor
- Cindy McReynolds Receives Major NIH Training Grant
- Cancer Team's Research Paper Named Journal of Clinical Investigation's Editor's Pick (Includes Bruce Hammock and Jun Yang)
Contacts:
- Bruce Hammock at bdhammock@ucdavis.edu
- Cindy McReynolds at cbmcreynolds@eicosis.com or cbmcreynolds@ucdavis.edu
- Jun Yang at junyang@ucdavis.edu